Merck & Company(MRK-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low118.00
Day High120.50
Open:120.03
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
Wells Fargo Keeps Their Buy Rating on Merck & Company (MRK)
Zacks Investment Research
Zacks Investment Ideas feature highlights: Eli Lilly and Merck
Zacks Investment Ideas feature highlights: Eli Lilly and Merck
Motley Fool
The Smartest Dividend ETF to Buy With $1,000 Right Now -- and It's Up 19% in 2026
Tipranks
Goldman Sachs Reaffirms Their Buy Rating on Merck & Company (MRK)
Motley Fool
Merck: Navigating the Patent Cliff and Future Growth Prospects
Zacks Investment Research
Sanofi Stock Falls 6% in 3 Months: Should You Buy, Sell or Hold?
Sanofi Stock Falls 6% in 3 Months: Should You Buy, Sell or Hold?
Zacks Investment Research
GSK Bets on Specialty Medicines to Drive Long-Term Revenue Growth
GSK Bets on Specialty Medicines to Drive Long-Term Revenue Growth
Zacks Investment Research
Can AstraZeneca's Expanding Cancer Portfolio Sustain Momentum?
Can AstraZeneca's Expanding Cancer Portfolio Sustain Momentum?
Tipranks
Merck & Company (MRK) Receives a Buy from UBS
Tipranks
Bernstein Remains a Hold on Merck & Company (MRK)
Tipranks
Scotiabank Sticks to Their Buy Rating for Merck & Company (MRK)
Motley Fool
Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Year, According to Wall Street
Motley Fool
Meet the Biotech Stock That's Trouncing Lilly, Merck, and Pfizer in 2026
Zacks Investment Research
Pfizer's Obesity and Oncology Pipeline Sets Up a Catalyst-Rich 2026
Pfizer's Obesity and Oncology Pipeline Sets Up a Catalyst-Rich 2026
Tipranks
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and HOYA (OtherHOCPF)
Tipranks
Barclays Reaffirms Their Buy Rating on Merck & Company (MRK)
Tipranks
Merck Shareholders Back Board, Pay and Auditor Ratification
Zacks Investment Research
Can MRK's New Drugs & Pipeline Aid Long-Term Growth Post Keytruda LOE?
Can MRK's New Drugs & Pipeline Aid Long-Term Growth Post Keytruda LOE?
Motley Fool
VYM vs. SCHD: Which U.S. Dividend ETF Is a Better Buy?

Profile

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.